Skip to content
Search

Latest Stories

UK virus reproduction number unchanged overall

The reproduction number of Covid-19 in the UK remains between 0.7 and 0.9, government scientists said on Friday (June 5), but has increased in parts of England after lockdown restrictions were eased.

Although the R number for the UK as a whole reflects the same rate of transmission as given last week, in England alone it is slightly higher - estimated to be between 0.7 and 1.


That could mean headaches ahead for prime minister Boris Johnson as he bids to re-open the economy in phases while avoiding a second peak of infections in what is already one of the world's hardest-hit countries.

Lockdown in England has been eased more quickly than Scotland, Wales, or Northern Ireland, where powers over measures are devolved.

"Our estimates show that the regional R numbers have increased although they remain below 1 for most of England – this is to be expected as we gradually move out of lockdown," said Yvonne Doyle, Medical Director of the Public Health England (PHE) agency.

"It is vital that everyone continues with social distancing, practising good hand hygiene and must remain at home and order a test if they have symptoms."

The reproduction, or R, number, measures the average number of people that one infected person will pass the virus on to. An R number above 1 can lead very rapidly to exponential growth.

A joint model produced by PHE and researchers at Cambridge University's MRC Biostatistics Unit said they believed the R number was below 1 in "all regions of England with the exception of the North West and the South West."

(Reuters)

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less